Immupharma Regulatory News (IMM)

FOR IMMEDIATE RELEASE

17 AUGUST 2012

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

Immupharma plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

On market transfer between indirect and direct funds

√

3. Full name of person(s) subject to thenotification obligation:

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):

Registered Holder:

BNY Norwich Union Nominees Limited 220,000*

Chase (GA Group) Nominees Limited 2,251,621*

*denotes direct interest

5. Date of the transaction and date onwhich the threshold is crossed orreached:

14 August 2012

6. Date on which issuer notified:

16 August 2012

7. Threshold(s) that is/are crossed orreached:

8. Notified details:

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary Shares

GB0033711010

Not Disclosable

Not Disclosable

2,471,621

2,471,621

Not Disclosable

3.03%

Not Disclosable

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,471,621

3.03%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

·; Aviva plc (Parent Company)

·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

 Tracy Weimar, Vice President Operations and Company Secretary

15. Contact telephone number:

 020 7152 4080

ImmuPharma PLC (www.immupharma.com)

Dr Robert Zimmer, President

+33 389 66 13 20

Dimitri Dimitriou, Chief Executive Officer 

+44 20 7152 4080

Richard Warr, Executive Chairman

+ 44 7766 232747

Lisa Baderoon, Head of Investor Relations

+44 7721 413 496

Buchanan

+ 44 20 7466 5000

Mark Court

Panmure Gordon & Co 

+44 20 7459 3600

Andrew Burnett, Fred Walsh

Cenkos Securities

+44 20 7397 8900

Stephen Keys, Camilla Hume (Corporate Finance)

Andy Roberts (Sales)

Espirito Santo Investment Bank

+44 20 7456 9191 

James Bromhead, Richard Crawley